BRODSKY & SMITH INVESTOR ALERT: Updates on Ongoing Investigations for 89bio, Inc. (Nasdaq - ETNB), Barinthus Biotherapeutics plc (Nasdaq - BRNS), Verint Systems Inc. (Nasdaq - VRNT), and Dayforce, Inc. (NYSE - DAY)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 16 2025
0mins
Source: Globenewswire
Investigation Announcements: Brodsky & Smith is reminding investors about ongoing investigations into several companies, including 89bio, Barinthus Biotherapeutics, Dayforce, and Verint Systems, regarding potential breaches of fiduciary duties by their boards during merger agreements.
Merger Details and Concerns: Each company is involved in a merger where the deal terms are being scrutinized for fairness, with specific concerns raised about whether the offered prices reflect fair value for shareholders, particularly in relation to recent stock performance highs.
Analyst Views on BRNS
Wall Street analysts forecast BRNS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRNS is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.759
Low
4.00
Averages
4.00
High
4.00
Current: 0.759
Low
4.00
Averages
4.00
High
4.00
About BRNS
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
